ProKidney Corp Ordinary Shares - Class A PROK
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
ProKidney to Host Virtual KOL Event to Recap Mechanism of Action Data Presented at ASN Kidney Week and Provide a Corporate Update
-
ProKidney Announces Eight Abstracts Selected for Presentation at the American Society of Nephrology’s Kidney Week 2026
-
ProKidney Announces Eight Abstracts Selected for Presentation at the American Society of Nephrology’s Kidney Week 2026
-
ProKidney Reports Second Quarter 2026 Financial Results and Business Highlights
Trading Information
- Previous Close Price
- —
- Day Range
- —–—
- 52-Week Range
- —–—
- Bid/Ask
- — / —
- Shares Outstanding
- 208.93M
- Market Cap
- —
- Volume/Avg
- — / —
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 280.04
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
ProKidney Corp is a clinical-stage biotechnology company pioneering the development of a first-in-class, autologous cell therapy that is intended to preserve kidney function in patients with advance chronic kidney disease (CKD) and diabetes. Its product candidate, REACT (Renal Autologous Cell Therapy), is a disease-modifying cell therapy made from a patient's renal cells. REACT has the potential to slow and stabilize the progression of chronic kidney disease. The company's pipeline consists of the development program for severe diabetic kidney disease.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- —
- Total Number of Employees
- 231
- Website
- https://www.prokidney.com
Valuation
|
Metric
|
PROK
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | — |
Price/Sales | 280.04 |
Price/Cash Flow | — |
Price/Earnings
PROK
Financial Strength
|
Metric
|
PROK
|
|---|---|
Quick Ratio | 8.04 |
Current Ratio | 8.36 |
Interest Coverage | −9,327.16 |
Quick Ratio
PROK
Profitability
|
Metric
|
PROK
|
|---|---|
Return on Assets (Normalized) | −45.01% |
Return on Equity (Normalized) | — |
Return on Invested Capital (Normalized) | −52.75% |
Return on Assets
PROK
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|$j?Sb< | LOCK|S&@X | $132B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|WJ$&T? | LOCK|N&q<D | $84B | |||
| Moderna Inc
MRNA
| LOCK|zWFJ<## | LOCK|MrW | $83B | |||
| argenx SE ADR
ARGX
| LOCK|Hd<^#T | LOCK|P% | $55B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|Kz#$YnK | LOCK|lh | $42B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|Z$!#<!# | LOCK|hr!Z | $30B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|&<@@zHX | LOCK|t%mfR | $29B | |||
| Incyte Corp
INCY
| LOCK|s^FBnKq | LOCK|$k | $24B | |||
| BioNTech SE ADR
BNTX
| LOCK|&%sKW% | LOCK|Gv& | $22B | |||
| BridgeBio Pharma Inc
BBIO
| LOCK|Rm$kWN | LOCK|T! | $14B |
United States